SAN FRANCISCO, May 8, 2018 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq:BOLD), a biotechnology company
focused on developing and commercializing innovative gene therapy
products for patients living with serious, life-threatening rare
diseases, today announced the promotion of Natalie Holles from Senior Vice President and
Chief Operating Officer to President and Chief Operating Officer.
In this new role, Ms. Holles will oversee the day-to-day
operations of the company, including research, development,
manufacturing, program management and corporate
development.
"Natalie is a decisive and results-oriented leader who has
inspired colleagues across Audentes through a period of rapid
growth and the achievement of important corporate milestones,"
stated Matthew R. Patterson, Chief
Executive Officer. "Today's announcement reflects an
evolution in our leadership structure which enables us to continue
to scale our organization effectively, achieve our ambitious goals
and execute on our mission to bring innovative gene therapy
products to patients living with serious, life-threatening rare
diseases."
Ms. Holles joined Audentes in 2015, bringing 15 years of
corporate development, strategic planning, and commercial
experience gained in a range of therapeutic areas and with a focus
on rare diseases. Prior to joining Audentes, Ms. Holles served as
Senior Vice President, Corporate Development at Hyperion
Therapeutics, Inc. from 2013 through its acquisition by Horizon
Pharma, plc in May 2015. From 2010 to
2013, Ms. Holles provided executive-level strategy and business
development advisory services to a number of privately-held
biopharmaceutical companies. Earlier in her career, Ms. Holles
served as Vice President, Business Development at KAI
Pharmaceuticals, Inc. (acquired by Amgen in 2012) and previously
held corporate development and commercial roles at InterMune, Inc.
(acquired by Roche in 2014) and Genentech, Inc. Ms. Holles holds an
M.A. in molecular, cellular and developmental biology from the
University of Colorado, Boulder, where
she was a Howard Hughes Medical Institute Predoctoral Fellow, and
an A.B. in Human Biology from Stanford
University.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on
developing and commercializing innovative gene therapy products for
patients living with serious, life-threatening rare diseases.
We are currently conducting Phase 1/2 clinical studies of our lead
product candidates AT132 for the treatment of X-Linked Myotubular
Myopathy (XLMTM) and AT342 for the treatment of Crigler-Najjar
Syndrome. We have two additional product candidates in
development, including AT982 for the treatment of Pompe disease,
and AT307 for the treatment of the CASQ2 subtype of
Catecholaminergic Polymorphic Ventricular Tachycardia
(CASQ2-CPVT). We are a focused, experienced and passionate
team committed to forging strong, global relationships with the
patient, research and medical communities.
For more information regarding Audentes, please visit
www.audentestx.com.
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
including, but not limited to: the company's ability to achieve key
corporate goals, including but not limited to anticipated clinical
milestones, the timing and nature of clinical development
activities, the timing of the release of data from ongoing clinical
trials, and the timing of regulatory filings. All statements
other than statements of historical fact are statements that could
be deemed forward-looking statements. Although the company
believes that the expectations reflected in such forward-looking
statements are reasonable, the company cannot guarantee future
events, results, actions, levels of activity, performance or
achievements, and the timing and results of biotechnology
development and potential regulatory approval is inherently
uncertain. Forward-looking statements are subject to risks and
uncertainties that may cause the company's actual activities or
results to differ significantly from those expressed in any
forward-looking statement, including risks and uncertainties
related to the company's ability to advance its product candidates,
obtain regulatory approval of and ultimately commercialize its
product candidates, the timing and results of preclinical and
clinical trials, fund development activities and achieve
development goals, establish and scale-up manufacturing processes
that comply with regulatory requirements, protect intellectual
property and other risks and uncertainties described under the
heading "Risk Factors" in documents the company files from time to
time with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date of this press
release, and the company undertakes no obligation to revise or
update any forward-looking statements to reflect events or
circumstances after the date hereof.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Paul Laland
415.519.6610
plaland@audentestx.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-announces-the-promotion-of-natalie-holles-to-president-and-chief-operating-officer-300643905.html
SOURCE Audentes Therapeutics, Inc.